Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum

Lung Cancer Clinical Trial

Official title:

Phase II Trial of Polyphenon E in Former Smokers With Abnormal Sputa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00573885
• Other study ID #: CDR0000578191
• Secondary ID: P01CA096964BCCA-
• Status: Completed
• Phase: Phase 2
• First received: December 13, 2007
• Last updated: March 7, 2012
• Start date: January 2008
• Est. completion date: December 2008

Study information

• Verified date: March 2012
• Source: British Columbia Cancer Agency
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Green tea extract may keep cancer from forming.

PURPOSE: This randomized phase II trial is studying green tea extract in preventing cancer in former and current heavy smokers with abnormal sputum.

Description:

OBJECTIVES:

• Evaluate the efficacy and safety of defined green tea catechin extract (polyphenon E) in former smokers with abnormal sputum score using stringent, newly developed response criteria of combined nuclear morphometry and malignancy-associated changes as the primary surrogate endpoint.

• Evaluate if polyphenon E can modulate other surrogate endpoint biomarkers of aberrant methylation, cell cycle regulation, apoptosis, oncogene/tumor suppressor gene expression, as well as phase I and II enzyme regulation.

• Establish a library of in-vivo confocal micro-endoscopy and optical coherent tomography images of the bronchial epithelium with corresponding histopathology, nuclear morphometry, and other biomarker information to assess the potential of confocal micro-endoscopy as a non-biopsy method to assess the effect of chemoprevention agents.

OUTLINE: This is an open label, part 1 study followed by a randomized, double-blind, part 2 study.

• Part 1 (completed March 22, 2006): Patients receive oral defined green tea catechin extract twice daily in months 1 and 2 and inhaled budesonide twice daily in month 2.

Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 1 and 2.

• Part 2: Patients are stratified by gender and randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral defined green tea catechin extract twice daily for 6 months.

• Arm II: Patients receive oral placebo twice daily for 6 months. Patients who have progressive or stable disease at 6 months may receive open-label defined green tea catechin extract.

Patients undergo autofluorescence bronchoscopy with biopsies, oral and bronchial brushing, and bronchoalveolar lavage at the end of months 6 and 12.

Blood samples are collected periodically for biomarker studies. After completion of study therapy, patients are followed periodically for 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: December 2008
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 45 Years to 74 Years

Eligibility

DISEASE CHARACTERISTICS:

• Current smokers who have smoked at least 30 pack-years (e.g., 1 pack per day for 30 years or more) (part 1; completed March 22, 2006)

• Former smokers who have smoked at least 30 pack-years (part 2)

• A former smoker is defined as one who has stopped smoking for one or more years

• Abnormal sputum score = 0.25 by computer-assisted image analysis

• Exhaled carbon monoxide level < 5 ppm (part 2 )

• Willing to take defined green tea catechin extract/placebo twice a day regularly

• No evidence of overt lung cancer

• No carcinoma in situ or invasive cancer on bronchoscopy or abnormal spiral chest CT suspicious of lung cancer

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status 0-1

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Creatinine normal

• Bilirubin normal

• AST and ALT normal

• Alkaline phosphatase normal

Exclusion criteria:

• Chronic active hepatitis/liver cirrhosis

• Severe heart disease (e.g., unstable angina, chronic congestive heart failure, use of antiarrhythmic agents)

• Ongoing gastric ulcer

• Acute bronchitis or pneumonia within one month

• Known reaction to lidocaine, albuterol sulfate, midazolam hydrochloride, and/or alfentanil hydrochloride

• Known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients

• Any medical condition, such as acute or chronic respiratory failure or bleeding disorder that, in the opinion of the investigator, could jeopardize the patient's safety during participation in the study

• Unwilling to have a bronchoscopy

• Unwilling to have a spiral chest CT

PRIOR CONCURRENT THERAPY:

• No more than 5 cups of tea a week

• No concurrent anticoagulant treatment such as warfarin or heparin

• No use of other natural health products containing green tea compounds

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Lung Cancer
• Tobacco Use Disorder

Intervention

Drug:
• defined green tea catechin extract
Given orally

Other:
• placebo
Given orally

Locations

Country	Name	City	State
Canada	British Columbia Cancer Agency - Vancouver Cancer Centre	Vancouver	British Columbia

Sponsors (3)

Lead Sponsor	Collaborator
British Columbia Cancer Agency	National Cancer Institute (NCI), University of Cincinnati

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in oncogene/tumor suppression gene expression (part 1; completed March 22, 2006)		36 months	No
Primary	Phase I and II enzyme regulation by Affymetrix chip analysis in bronchial brush cells (part 1)		60 months	No
Primary	C-reactive protein level in plasma before treatment and 1 and 2 months after treatment (part 1)		60 months	No
Primary	Quantitative sputum score by image analysis before and 6 months after treatment (part 2)		36 months	No
Secondary	Change in pathology grade of bronchial biopsies (part 2)		36 months	No
Secondary	Morphometric index of bronchial biopsies and bronchoalveolar lavage cells (BAL) (part 2)		36 months	No
Secondary	Methylation markers in sputa and BAL cells (part 2)		60 months	No
Secondary	Ki-67 expression (part 2)		60 months	No
Secondary	Cleaved caspase 3, p53, and VEGF assays in bronchial biopsies (part 2)		60 months	No
Secondary	Oncogene and tumor suppression gene expression (part 2)		60 months	No
Secondary	Phase I and II enzyme regulation by Affymetrix chip analysis of RNA from bronchial brush cells (part 2)		60 months	No
Secondary	C-reactive protein levels in plasma before treatment, and 6 months after treatment (part 2)		36 months	No
Secondary	Resolution or progression of non-calcified lung nodules on spiral CT (part 2)		60 months	No